What is Thrombolex?
Founded in 2016, Thrombolex operates as a specialized medical device company dedicated to the design, development, and distribution of advanced endovascular catheters. The company focuses on addressing the clinical challenges associated with arterial, venous, and arteriovenous thromboembolic conditions. Its core competency lies in catheter-directed thrombolysis (CDT), a minimally invasive procedure that allows for the targeted delivery of therapeutic agents to dissolve blood clots.
By providing clinicians with high-precision tools, Thrombolex occupies a vital niche in the interventional medical device market. The company's commitment to engineering excellence and clinical efficacy has established it as a key player in the treatment of life-threatening vascular obstructions. As the demand for less invasive, highly effective interventional procedures continues to rise, Thrombolex remains uniquely positioned to capture significant market share through its specialized product portfolio.
How much funding has Thrombolex raised?
Thrombolex has raised a total of $50M across 1 funding round:
Series A
$50M
Series A (2026): $50M with participation from OrbiMed
Key Investors in Thrombolex
OrbiMed
OrbiMed is a premier healthcare-focused investment firm that manages capital across the biopharmaceutical, medical device, and digital health sectors, providing both financial resources and deep operational expertise to its portfolio companies.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Thrombolex?
Looking ahead, the strategic deployment of this recent financing will likely focus on scaling commercial infrastructure and accelerating the adoption of its endovascular platforms. The company is expected to prioritize clinical evidence generation and market expansion, ensuring that its technology reaches a broader patient demographic across both domestic and international healthcare systems.
Furthermore, the backing from top-tier healthcare investors provides Thrombolex with the operational expertise necessary to navigate the complex regulatory and commercial landscapes of the medical device industry. As the firm transitions into its next phase of growth, the focus will remain on optimizing its supply chain, fostering strategic partnerships with leading hospital networks, and continuing its trajectory of innovation in the management of thromboembolic diseases.
